TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration (“AMD”) and fibrotic diseases. Our lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the VEGF pathway. Our other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In March 2014, Santen Pharmaceutical Co., Ltd., a global ophthalmology company, licensed from us exclusive worldwide rights to develop and commercialize our anti-endoglin antibodies for ophthalmology indications, including AMD. We retain global rights to develop and commercialize our anti-endoglin antibodies outside of the field of ophthalmology, as well as global rights to TRC102 in all indications.
Type
Public
HQ
San Diego, US
Founded
2006
Employees
22 (est)

Key People at TRACON Pharmaceuticals

Charles P. Theuer

Charles P. Theuer

President and CEO

TRACON Pharmaceuticals Locations

San Diego, US

TRACON Pharmaceuticals Metrics

TRACON Pharmaceuticals Summary

Founding Date

2006

Market capitalization

$75.1 M

Closing share price

$5.6

TRACON Pharmaceuticals Market Value History

TRACON Pharmaceuticals News

TRACON Pharmaceuticals Company Life

You may also be interested in